Drug: Lyrica
Company: Pfizer
Total spend Q1, 2012: $25.1 million
Total spend Q1, 2011: $30.8 million
Watch the TV commercial here >>

While Pfizer is remaking itself in a world without Lipitor exclusivity, it will at least be able to carry forward with protection another 5 years on its super blockbuster drug Lyrica. A federal judge in July upheld its patents for Lyrica, the pain drug and epilepsy treatment. Released in 2004, the drug first topped the $1 billion sales milestone in 2008 and its sales have just kept growing. Last year, Lyrica generated $3.7 billion in revenue. Federal authorities did say that some of that success was attributable to misbehavior. Lyrica was one of the drugs included in Pfizer's $2.3 billion marketing settlement in 2009. But that is past and the drug keeps generating big sales, including $458 million in the first quarter, says, which translates as a 6% jump.


Suggested Articles

Drug pricing remains the pharma industry's top concern in 2020, execs said in a survey, as political threats continue from Washington, D.C.

Allergan updated its Botox marketing for chronic migraine by featuring strong women powering through their too-frequent migraine days.

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.